Concepedia

Natalyn Hawk

NH

Statistics

Publications

10

Citations

799

H-Index

10

Active since

2002

Affiliations

Emory University(Current)

Piedmont Cancer Institute

Merck & Co., Inc., Rahway, NJ, USA (United States)

Eisai (United States)

Natalyn Hawk is an author at Emory University specializing in medicine, oncology, and gastrointestinal oncology.

Publications per year

2002–2022

10

Publications

10

Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma

Hemchandra Mahaseth, Edith Brutcher, John Kauh et al. · Pancreas · 2013 · 201 citations

, , +17

Colorectal Cancer Initial Diagnosis: Screening Colonoscopy, Diagnostic Colonoscopy, or Emergent Surgery, and Tumor Stage and Size at Initial Presentation

Courtney C. Moreno, Pardeep Mittal, Patrick S. Sullivan et al. · Clinical Colorectal Cancer · 2015 · 163 citations

, , +17

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

Ana Arance, Luis de la Cruz‐Merino, Teresa M. Petrella et al. · Journal of Clinical Oncology · 2022 · 127 citations

, , +17

Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach

Malcolm H. Squires, Volkan Adsay, David M. Schuster et al. · Annals of Surgical Oncology · 2015 · 104 citations

, , +16

Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy

Xuerong Wang, Natalyn Hawk, Ping Yue et al. · Cancer Biology & Therapy · 2008 · 84 citations · Full text

, , +17

1–5 of 10